Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Clementia completes patient enrolment in phase 3 of MOVE Trial
  2. Genentech doses first patient in Perjeta and Herceptin Phase 3 study
  3. Ultragenyx doses first patient in DTX401 Phase 1/2 study to treat GSDIa
  4. Biohaven initiates Phase 2/3 clinical trial of trigriluzole
  5. Seattle Genetics completes enrolment in EV-201 trial

Latest Content

Eyenovia announces positive results of EYN PG21 clinical trial

Eyenovia, a company developing a pipeline of ophthalmology products using its patented piezo-print technology, has announced positive results of its EYN PG21 clinical trial of microdose latanoprost for reducing intraocular pressure (IOP) and patient usability.

Novocure and US Oncology Research partner for PANOVA-3 trial

Novocure has partnered with US Oncology Research to conduct the PANOVA-3 trial, a Phase lll study evaluating the efficacy of Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine for the treatment of patients with unresectable locally advanced pancreatic cancer.

TLC doses first patients in Phase I/II study of TLC590

Taiwan Liposome Company (TLC) has dosed the first patients in a Phase I/II trial to investigate TLC590 in comparison with free, non-liposomal ropivacaine when given as a single infiltrative local administration for the treatment of adult patients following inguinal hernia repair surgery.

Quick and Flexible Elemental Screening with Omnian

Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.

Sorrento treats first patient in PTVA-OA-001 trial of RTX

Sorrento Therapeutics has treated the first patient enrolled in the PTVA-OA-001 trial and is set to continue the study after the data monitoring committee (DMC) found no safety concerns associated with the drug in a scheduled safety assessment.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top